Noninvasive Imaging of Heart Failure: A Pilot Study

This study is currently recruiting participants. (see Contacts and Locations)
Verified March 2014 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT01160471
First received: July 9, 2010
Last updated: April 10, 2014
Last verified: March 2014
  Purpose

Background:

- Heart failure is a common cardiovascular disorder whose incidence increases with age, affecting up to 10% of people older than 65 years of age. As the population ages, the prevalence and cost of heart failure will continue to rise. Researchers are interested in using noninvasive imaging methods to better understand the symptoms and effects of heart failure.

Objectives:

- To conduct a noninvasive comparative imaging study of individuals with heart failure.

Eligibility:

- Individuals at least 18 years of age who have been diagnosed with heart failure (with at least mild symptoms and slight limitations on physical activity).

Design:

  • This study will last approximately 2 years and will require four visits to the National Institutes of Health Clinical Center, with one screening visit and three study visits.
  • Participants will be screened with a full medical history and physical examination, as well as blood and urine samples.
  • Participants will have the following tests during each study visit:
  • Physical examination
  • Blood and urine samples
  • Cardiac magnetic resonance imaging
  • Cardiac computerized tomography to study the blood vessels in and leading to the heart
  • Echocardiogram to evaluate heart function
  • Electrocardiogram to measure heart electrical activity
  • The three study visits will take place 1 year apart. Participants will also receive follow-up phone calls 6 months after the first and second visits.
  • No treatment will be provided as part of this protocol.

Condition
Magnetic Resonance Imaging
Acquired Heart Disease
Myocardial Fibrosis

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Noninvasive Imaging of Heart Failure

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • Post contrast myocardial T1 measured by CMR.

Secondary Outcome Measures:
  • A) Post contrast myocardial attenuation measured by MDCT. B) LV systolic/diastolic function measured by CMR. C) Serum myocardial extracellular matrix remodelling biomarkers. D) Fibrosis detected by histology analysis in endomyocardial biopsy.

Estimated Enrollment: 196
Study Start Date: June 2010
Detailed Description:

More than 9% of American men and close to 5% of women ages 60 to 79 years report a diagnosis of heart failure, where above the age of 80 years these figures increase to 13.8% and 12.2%, respectively. Projection into the middle part of this century suggests that, as the population ages, the prevalence and cost of heart failure will continue to rise. The primary aim of this proposal is to investigate noninvasive imaging methods for quantifying diffuse myocardial fibrosis with cardiac magnetic resonance imaging (CMR) in heart failure patients. The secondary aims are to investigate the association between diffuse fibrosis detected by CMR with left ventricular function, and examine the utility of multi-detector CT (MDCT) in detecting diffusion myocardial fibrosis.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

The common inclusion criteria between patients and controls are:

A. Able to understand and sign informed consent.

B. Able to complete a MRI or CT scan.

C. Age greater than or equal to 18 years old.

Heart Failure subject:

D. Men and women with a clinical diagnosis of heart failure.

E. New York Heart Association functional class II or worse.

F. For the normal ejection fraction arm.

  1. Preserved left ventricular ejection fraction (EF > 50%)
  2. Diastolic dysfunction defined one or more of the following

    1. LVEDP > 16 mm Hg
    2. PCW > 12 mm Hg
    3. E/E ratio > 15
    4. E/E ratio > 8 AND NT-proBNP > 220 pg/mL

    For the systolic dysfunction arm:

  3. Left ventricular ejection fraction < 40%

    Normal Control:

    G. Men and women without a clinical diagnosis of heart failure.

    H. NIH employees may be involved and NIH requirements will be followed as laid out in NIH Policy Manual 2300-630-3 - Leave Policy For NIH Employees Participating In NIH Medical Research Studies.

    EXCLUSION CRITERIA:

    Individuals will be excluded from the study if they are discovered to have coexistent conditions that may contribute to structural or functional cardiac abnormalities, which may confound interpretation of results, are ineligible for MRI or if they are at increased risk for Nephrogenic Systemic Fibrosis (NSF) including:

    A. Contra indications for gadiolinium-based contrast agent:

    1. eGFR < 30ml/min/1.73m(2)
    2. Acute renal failure, renal transplantation, current dialysis treatment or hepatorenal syndrome
    3. History of liver transplantation or severe liver disease
    4. Severe Asthma
    5. Hemoglobinopathies, sickle cell anemia and thalassemias major
    6. History of multiple myeloma
    7. History of significant allergic reaction to gadolinium-based contrast agents

    B. Coronary artery disease with unstable symptoms or acute coronary syndrome within the last six months.

    C. Medical conditions associated with increased collagen turnover which may confound interpretation of biomarkers of collagen synthesis. Examples include systemic amyloid disease, cirrhosis, liver, pulmonary, or renal fibrosis, inflammatory states, cancer, recent trauma or surgery;

    D. Pregnant or lactating women;

    E. Mental, neurologic or social condition preventing understanding of the rationale, procedures, risks and potential benefits associated with the trial;

    F. Any other conditions that precludes safety for MRI or MDCT per the researcher s evaluation.

    G. Patients otherwise eligible but with any of the following contraindications for iodine-based CT contrast agent will be excluded from contrast CT angiography but may undergo all other study procedures:

    1. Renal dysfunction (defined as eGFR < 45 mL/min/m(2))
    2. Current clinical diagnosis of renal failure
    3. Prior hypersensitivity to iodine containing substances (shellfish, iodine, and or previous contrast reactions to contrast agents.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01160471

Contacts
Contact: Marissa B Mallek (301) 496-7700 marissa.mallek@nih.gov
Contact: David A Bluemke, M.D. (301) 402-1854 bluemked@mail.nih.gov

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010    prpl@mail.cc.nih.gov   
Sponsors and Collaborators
Investigators
Principal Investigator: David A Bluemke, M.D. National Institutes of Health Clinical Center (CC)
  More Information

Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT01160471     History of Changes
Other Study ID Numbers: 100153, 10-CC-0153
Study First Received: July 9, 2010
Last Updated: April 10, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Heart Failure
Computed Tomography
Ultrasound
Fibrosis
Biomarker

Additional relevant MeSH terms:
Fibrosis
Heart Diseases
Heart Failure
Pathologic Processes
Cardiovascular Diseases

ClinicalTrials.gov processed this record on August 21, 2014